Statin intolerance - a question of definition

Engi Abdel-Hady Algharably1,2, Iris Filler1, Stephanie Rosenfeld3

  • 1a Institut für Klinische Pharmakologie und Toxikologie , Charité - Universitätsmedizin Berlin , Berlin , Germany.

Abstract

Insights

Statin intolerance, often causing muscle symptoms, prevents effective cardiovascular risk reduction. A common definition is needed for consistent clinical use and research of statin therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Statin therapy is crucial for lowering low-density lipoproteins cholesterol and preventing cardiovascular disease.
  • Statin intolerance is defined as the inability to continue statin therapy due to side effects, most commonly muscle symptoms.
  • Current definitions of statin intolerance vary, hindering comparable clinical study results.

Purpose of the Study:

  • To review published definitions of statin intolerance.
  • To provide a brief overview of clinical aspects and risk factors associated with statin intolerance.
  • To suggest features for a common definition of statin intolerance.

Main Methods:

  • Literature review of published definitions of statin intolerance.
  • Analysis of clinical aspects and risk factors.
  • Synthesis of features for a consensus definition.

Main Results:

  • No universally accepted definition of statin intolerance exists from major drug regulatory agencies.
  • Disparate definitions used in clinical studies lead to non-comparable outcomes.
  • Lack of consensus among medical associations complicates clinical management.

Conclusions:

  • There is a significant unmet need for a common definition of statin intolerance.
  • Establishing a consensus definition is essential for appropriate clinical use and effective research.
  • Further work is required to develop a widely accepted definition for improved patient outcomes and research standardization.

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
605
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
1.8K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
860
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
1.1K